Establishment of Preclinical Models from Patients with Gynecological Malignancies

Overview

Información sobre este estudio

Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving outcomes in this subgroup of patients is the paucity of tumor models that can mimic patient characteristics to study novel therapies. Patient-derived xenograft (PDX) models are considerate the most representative pre-clinical model of human cancer, recapitulating the key characteristics of the original patient tumor. Other preclincal models to test drug effcicacy includes ex vivo 3D culture and 2D culture systems. In this study, we make and test preclinical models of gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, vulvar, cervix, and vaginal) of any histologic subtype using surplus tumor specimens obtained at the time of routine tumor biopsy procedure, or clinically-indicated surgery.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Females of age ≥ 16 years at pre-registration.
  • Previous diagnosis of gynecological malignancy (any histology, grade and stage) and current diagnosis of new or recurrent disease.
  • Patient will meet one of these two criteria for tissue.
  • Patient has disease amenable to biopsy and is agreeable to undergo a biopsy. 
    • NOTE:  Under unusual circumstances, submission of pleural fluid or ascites material may be acceptable if a biopsy is not possible. This will require approval by one of the study Principal Investigators.
  • Patient has disease amenable to be surgically resected and is agreeable to undergo the surgical procedure.
  • Ability to provide written informed consent.

Exclusion Criteria:

  • Women known to be pregnant are excluded.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Saravut Weroha, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Valentina Zanfagnin M.D.

(507) 538-5933

zanfagnin.valentina@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Saravut Weroha, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available

Información adicional de contacto

Formulario de contacto para ensayos sobre cáncer

Teléfono: 855-776-0015 (toll-free)

Preguntas de estudios clínicos para pacientes internacionales